Business Description
XTL Biopharmaceuticals Ltd
ISIN : US98386D3070
Share Class Description:
FRA:HHB0: ADRTotal Employee Number:
2Compare
Compare
Traded in other countries / regions
XTLB.IsraelXTLB.USAHHB0.Germany IPO Date
2007-03-15Description
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | -1.53 | |||||
Debt-to-Equity | -1.06 | |||||
Debt-to-EBITDA | -0.36 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 24.6 | |||||
3-Year EPS without NRI Growth Rate | -18.6 | |||||
3-Year FCF Growth Rate | 15.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.51 | |||||
9-Day RSI | 51.49 | |||||
14-Day RSI | 51.97 | |||||
3-1 Month Momentum % | -0.78 | |||||
6-1 Month Momentum % | -22.42 | |||||
12-1 Month Momentum % | -44.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.4 | |||||
Quick Ratio | 0.4 | |||||
Cash Ratio | 0.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.2 | |||||
Shareholder Yield % | -0.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -14583.33 | |||||
OCF Margin % | -14583.33 | |||||
ROE % | -407.23 | |||||
ROA % | -221.7 | |||||
ROIC % | -44.64 | |||||
3-Year ROIIC % | 458.72 | |||||
ROC (Joel Greenblatt) % | -424.86 | |||||
ROCE % | -37.34 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 3 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -9.32 | |||||
EV-to-EBITDA | -9.32 | |||||
EV-to-FCF | -6.84 | |||||
Earnings Yield (Greenblatt) % | -10.73 | |||||
FCF Yield % | -14.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
XTL Biopharmaceuticals Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.006 | ||
| EPS (TTM) (€) | -2.764 | ||
| Beta | 4.3371 | ||
| 3-Year Sharpe Ratio | 0.36 | ||
| 3-Year Sortino Ratio | 1.18 | ||
| Volatility % | 96.89 | ||
| 14-Day RSI | 51.97 | ||
| 14-Day ATR (€) | 0.097718 | ||
| 20-Day SMA (€) | 2.306 | ||
| 12-1 Month Momentum % | -44.83 | ||
| 52-Week Range (€) | 1.59 - 16 | ||
| Shares Outstanding (Mil) | 2.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
XTL Biopharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
XTL Biopharmaceuticals Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-18 | In 100 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 10 days | ||
| First quarter earnings results for 2026 | 2026-08-07 | 2.28 (+0.00%) | ||
| General meeting for 2026 | 2026-08-04 | 2.26 (+0.00%) | ||
| Annual report for 2025 | 2026-06-30 | 1.88 (+0.00%) | ||
| 0.25:1 Stock Split | 2026-03-25 | 1.84 (+1.32%) | ||
| General meeting for 2025 | 2025-07-21 16:00 | 5.84 (+0.00%) | ||
| Annual report for 2024 | 2025-04-30 | 3.96 (-13.16%) | ||
| Third quarter earnings results for 2024 | 2024-12-31 | 7.72 (+0.00%) | ||
| 0.2:1 Stock Split | 2017-02-10 | 10.54 (+0.00%) |
Show
Entries
XTL Biopharmaceuticals Ltd Frequently Asked Questions
What is XTL Biopharmaceuticals Ltd(FRA:HHB0)'s stock price today?
The current price of FRA:HHB0 is €2.30. The 52 week high of FRA:HHB0 is €16.00 and 52 week low is €1.59.
When is next earnings date of XTL Biopharmaceuticals Ltd(FRA:HHB0)?
The next earnings date of XTL Biopharmaceuticals Ltd(FRA:HHB0) is 2026-08-20 Est..
Does XTL Biopharmaceuticals Ltd(FRA:HHB0) pay dividends? If so, how much?
XTL Biopharmaceuticals Ltd(FRA:HHB0) does not pay dividend.
Press Release
Articles on XTL Biopharmaceuticals Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers